¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06
±³À°ÀÏÀÚ : 2023-04-06
±³À°Àå¼Ò : ¾Ú¹ö¼­´õ ¼­¿ï Ç®¸¸È£ÅÚ

±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 80,000¿ø  

ºñ°í Àü°øÀÇ,°£È£»ç,±âŸ 50000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:15~09:35 Current status of hemophilia care in China Renchi Yang(Institute of Haematology and Blood Diseases Hospital, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:35~09:55 Current Situation and Issues in Hemophilia in Japan Michio Sakai(Munakata Suikokai General Hospital, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:55~10:15 Current Situation and Issues in Hemophilia in Korea Ki-Young Yoo(Korea Hemophilia Foundation, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:15~10:35 Current Situation and Issues in Hemophilia in Taiwan Chia-Yao Chang(Taipei Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:35~10:55 Current therapeutic landscape and future directions in the management of haemophilia in Australia Huyen Tran(Australia Haemophilia Centre Directors)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 11:20~12:00 Advances in hemophilia A treatment after emicizumab Midori Shima(Thrombosis and Hemostasis Research Center, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 12:10~12:50 Optimizing the benefits of personalized prophylaxis based on the real world experience Robert Klamroth(Vivantes Klinikum Friedrichshain, Germany)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:00~13:20 Emicizumab for Individual Needs of Japanese People Living with Hemophilia: Impacts and Unsolved Issues Ei Kinai(Tokyo Medical University, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:20~13:40 The role of low-dose prophylaxis and low-dose ITI for hemophilia children in developing countries. Runhui Wu(Beijing Children¡¯s Hospital, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:40~14:00 Individualized Treatment Using Population Pharmacokinetics for Patients with Hemophilia in Taiwan Yeu-Chin Chen(Tri-Service General Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:00~14:20 Current treatment pattern in hemophilia, based upon data the HIRA(health insurance review agency) and KBDR (Korean bleeding disorder registry) Jung Woo Han(Yonsei University Health System, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:45~15:05 Hemophilia patients with Inhibitors in China Wei Liu(Blood Diseases Hospital (Institute of Hematology), China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:05~15:25 The frontiers of diagnosis and treatment in Japanese hemophilia patients with inhibitors based on prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2) Koji Yada(National Hospital Organization Osaka National Hospital, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:25~15:45 Current status in hemophilia patients with inhibitors in Korea YoungShil Park(Kyung Hee University Hospital, Korea)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:45~16:05 Efficacy, safety, and cost of emicizumab prophylaxis in hemophilia A patients with inhibitor: a nationwide observation study in Taiwan Jiaan-Der Wang(Taichung Veterans General Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:30~16:50 Clinical hemostasis prediction through current monitoring technology in bleeding disorders Naruto Shimonishi(Nara Medical University, Japan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:50~17:10 The application of NGS for the diagnosis of hereditary platelet disorders Donglei Zhang(Zhongnan Hospital of Wuhan University, China)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:10~17:30 Laboratory monitor of factor VIII: perceive in the era of emicizumab Te-Fu Weng(Chung Shan Medical University Hospital, Taiwan)

±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:30~17:50 Application of primary data of coagulometer assays Jae Woo Song(Yonsei University Health System, Korea)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѼºÇü¿Ü°úÇÐȸ Àü³²´ëÇб³ Çе¿Ä·ÆÛ½º ÀÇ»ý¸í¿¬±¸¿ø 1Ãþ ´ëȸÀÇ½Ç : 2023-04-07
´ÙÀ½±Û ´ëÇѼÒÈ­±âÇÐȸ ±¤ÁÖÀü³²Áöȸ Ãá°è ¼¼¹Ì³ª : 2023-04-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 50 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 36 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 38 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 48 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 40 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 34 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 13 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 13 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 31 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 16 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 14 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 34 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 26 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 30 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 23 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷